Risk of recurrent venous thromboembolism after a first oestrogen-associated episode: Data from the REVERSE cohort study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: The use of exogenous oestrogen in women with otherwise unprovoked venous thromboembolism (VTE) could be considered sufficient explanation to classify VTE as provoked if the risk of recurrent VTE after 3–6 months of anticoagulant treatment is similar to the risk of recurrent VTE observed after a surgery or prolonged immobilisation. Our objective was to assess the risk of recurrent VTE in women after a first unprovoked episode on oestrogen. The REVERSE study is a cohort study of patients with a first unprovoked VTE treated with anticoagulant treatment for 5–7 months. The risk of recurrent VTE during follow-up was compared between women users and non users of oestrogen at the time of index VTE. Among the 646 patients included, 314 were women, of them 67 were current users of oestrogen at the time of their VTE: 49 were on oral contraceptives and 18 on post-menopausal hormone replacement therapy (HRT). No significant association was found between oestrogen exposure, either oral contraceptives or HRT, and a lower risk of recurrent VTE after adjustment for age, or analysis restricted to women in the same age range as oestrogen contraceptives and HRT users, respectively. The risk of recurrent VTE is low in women after a first otherwise unprovoked oestrogen-associated VTE. However, this risk is not significantly lower than in women whose VTE was not related to oestrogen use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baglin, T., Luddington, R., Brown, K., & Baglin, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14111-6 · Cited by 694
d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054444 · Cited by 622
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450302 · Cited by 591
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581 · cited 4×
“Therefore, among women included in the REVERSE study – a cohort study designed to derive a clinical decision rule for recurrent VTE in patients who discontinued anticoagulant treatment after 5–7 months for a first unprovoked VTE (13), we assessed the annual risk of recurrent VTE in women on oestrogen therapy at the ti…”
BackgroundMethodInfluentialSelf-citationCanonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569 · cited 1×
“therapy is associated with an increased risk of VTE in women: three- to four- and a two- to three-fold increased risk on oestrogen oral contraceptive or postmenopausal hormone replacement therapy (HRT), respectively (9, 10).”
BackgroundEffect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.
McRae, S., Tran, H., Schulman, S., Ginsberg, J., & Kearon, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69110-1 · Cited by 289 · cited 1×
“It has also emerged over the last five years that men are at higher risk of recurrent VTE than women (5, 13, 17), introducing the possibility that gender and exogenous oestrogen use confounds their individual associations with the risk of recurrent VTE.”
Background
Cited by
Epidemiology of venous thromboembolism
Heit, J. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.83 · Cited by 1,277
The epidemiology of venous thromboembolism
Heit, J. A., Spencer, F. A., & White, R. H. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1311-6 · Cited by 1,093
Self-citationRisk of recurrence after venous thromboembolism in men and women: patient level meta-analysis
Douketis, J., Tosetto, A., Marcucci, M., Baglin, T., Cosmi, B., Cushman, M., Kyrle, P., Poli, D., Tait, R. C., & Iorio, A. (2011) · BMJ · doi:10.1136/bmj.d813 · Cited by 278
Rodger, M. A., Le Gal, G., Anderson, D. R., Schmidt, J., Pernod, G., Kahn, S. R., Righini, M., Mismetti, P., Kearon, C., Meyer, G., et al. (2017) · BMJ · doi:10.1136/bmj.j1065 · Cited by 238
Self-citationDouketis, J., Tosetto, A., Marcucci, M., Baglin, T., Cushman, M., Eichinger, S., Palareti, G., Poli, D., Tait, R. C., & Iorio, A. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-8-201010190-00009 · Cited by 175
Metadata
- Authors
- Gal, G. L., Kovacs, M., Carrier, M., Do, K., Kahn, S., Wells, P., Anderson, D., Chagnon, I., Solymoss, S., Crowther, M., Righini, M., Lacut, K., White, R., Vickars, L., & Rodger, M.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2010
- Volume
- 104
- Issue
- 09
- Pages
- 498-503
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2096599872
- Cited by
- 68
- References
- 6
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of recurrent venous thromboembolism after a first oestrogen-associated episode: Data from the REVERSE cohort study. https://app.cochat.ai/papers/10.1160/th09-10-0685
- The paper
- Gal, G. L., Kovacs, M., Carrier, M., Do, K., Kahn, S., Wells, P., Anderson, D., Chagnon, I., Solymoss, S., Crowther, M., Righini, M., Lacut, K., White, R., Vickars, L., & Rodger, M. (2010). Risk of recurrent venous thromboembolism after a first oestrogen-associated episode: Data from the REVERSE cohort study. Thrombosis and Haemostasis. https://doi.org/10.1160/th09-10-0685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.